Systematic Review and Meta-Analysis on Rimegepant for Migraine Treatment

5 randomized controlled trials, comprising data from 5,565 participants, were analyzed in this systematic review and meta-analysis. The study, authored by Tong An and published on figshare in 2026, evaluates the efficacy and safety of rimegepant for acute migraine treatment. It reports statistically significant pain relief and freedom from Most Bothersome Symptom at 2 hours, but no significant effect on pain relapse from 2 to 48 hours.

Use Cases

• Training models to predict treatment efficacy based on meta-analysis results like risk ratios and confidence intervals.
• Analyzing safety profiles of migraine drugs based on reported adverse event data.
• Conducting secondary research on clinical trial methodologies for neurological conditions.
• Comparing short-term versus sustained therapeutic effects in pharmacological interventions.

Strengths

• Analysis is based on 5 randomized controlled trials, a standard for clinical evidence.
• Includes data from 2,715 individuals treated with rimegepant and 2,850 control participants.
• Employs GRADEprofiler and Cochrane Collaboration tools for evidence quality and bias assessment.
• Reports specific statistical outcomes, including risk ratios and confidence intervals for key efficacy measures.

Limitations

• The dataset is a 243 KB DOC file; the underlying tabular meta-analysis data is not directly accessible.
• Row count and column-level documentation are unknown, limiting direct data analysis.
• The authors note limitations in the quality and quantity of included trials, suggesting findings require confirmation.

Provenance

Source

figshare, author Tong An.

Collection Method

Systematic search of public databases for randomized controlled trials, analyzed using a random-effects model.

Time Range

Database searches from inception until February 2025.

Freshness

Last updated 2026-05-01 04:17:45.